Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics

The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems

Date

10 Sep 2022

Session

ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics

Topics

Cancer Biology;  Laboratory Diagnostics;  Pathology/Molecular Biology;  Translational Research;  Digital Health and Real World Data (eHealh, Telehealth, Big Data);  Targeted Therapy;  Molecular Oncology;  Genetic and Genomic Testing, Counseling

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Oliver Gautschi

Authors

O. Gautschi

Author affiliations

  • Medical Oncology Department, Luzerner Kantonsspital, 6210 - Sursee/CH
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.